PRENATAL GENETICS TEST REQUISITION FORM



All sections on this page are required unless otherwise specified. Incomplete information could result in a delay of testing.

PATIENT INFORMATION							
First Name			Last Name				
Fetal Sex: O Male O Female			Date of Birth (mm/dd/yy)				
Fetal Karyotype (if known):							
Email							
Address							
City				Zip Code			
Phone (mobile preferred)	Is this fetus deceased? OYes ONo Deceased Date:						
	SAMPLE INF	ORM <i>i</i>	ATION				
Specimen ID	Medical Record #		Date Sample C	collected (mm/dd/yy)			
Back-up culture maintain	ed at an outside la	p. (Yes O No				
☐ Positive control ☐ Chorionic Villi (CV) ☐ Amniotic Fluid ☐ Fetal Blood (PUBS) ☐ Cultured CV ☐ Cultured Amniocytes ☐ Products of Conception (POC), specify tissue:							
DNA: specify source							
☐ Maternal blood for MCC (please send for ALL studies)							
☐ Paternal blood (please ☐ Parental follow-up	send for ALL molec	ular stud	ies)				
Father's Last Name	Father's First Name	Э	Father's Date of	of Birth (mm/dd/yy)			

ORDERING PROVIDER ATTESTATION

By signing this form, the ordering provider attests that (i) he/she authorizes and directs GeneDx to perform the testing indicated; (ii) he/she is the ordering provider and is authorized by law to order the test(s) requested; (iii) any test(s) requested on this Test Requisition Form ("TRF") are reasonable and medically necessary for the diagnosis or treatment of a disease, illness, impairment, symptom, syndrome or disorder; (iv) the test results will determine the patient's medical management and treatment decisions of this patient's condition on this date of service; (v) the patient or the individual/family member authorized to make decisions for the patient (collectively, the "patient"), in addition to any relatives', when applicable, has been supplied with information regarding genetic testing, and has consented to undergo genetic testing; (vi) the full and appropriate diagnosis codes are indicated to the highest level of specificity; (vii) he/she will not seek reimbursement from any third party, including but not limited to federal healthcare programs if testing is covered by GeneDx and will inform the patient of the same; (viii) GeneDx may share contact information for the ordering provider and other healthcare providers listed on the this order with third parties regarding the requested genetic testing and potential clinical trial or study opportunities; and (ix) the patient or the individual/ family member authorized to be contacted via the email address or mobile phone number provided for this and future testing. lacksquare New York Retention Opt-In. By checking this box, I confirm that the patient is a New York State resident who gives permission for GeneDx to retain any remaining sample longer than 60 days after testing has been completed. $\hfill \square$ **Patient Research Opt-Out.** By checking this box, I confirm that the patient wishes to opt out of being contacted for research studies. ☐ Health Information Exchange Opt-in. Check this box if your patient resides in CA, FL, MA, NV, NY, RI, and VT and wishes to opt-in to having their information shared for

☐ Health Information Exchange Opt-out. Check this box if your patient resides in any other US state or territory and wishes to opt-out of participation in Health Information

Date

						,
	ACCOU	NT IN	FORMA ¹	TION		
GeneDx Account Nu	mber		Account No	ame		
Phone			Fax			
Address						
City			State		Zip Cod	e
Ordering Provider N	ame				Role/Tit	le
NPI			Phone Num	nber	ı	
Send Report Via: Fax #/Email:	Fax Email 🗆 f	Portal				
Additional Ordering	Provider Name (o	ptional)		Role/Tit	le
NPI						
Send Report Via: Fax #/Email:	Fax Email F	Portal				
SEND ADDITIONAL R	EPORT COPIES TO (ptiona	I)			
Provider Name			GeneDx Aco	ct#		
Fax #/Email:						
	ICD-	10-C	M CODE	S		
ICD-10-CM Codes to	support all test(s)	ordere	d			
Clinical Diagnosis					Age of C	Onset
	PAYMENT O	PTIO	NS (Sele	ect One)	
O INSURANCE BILL	Patient Status					
Select all that apply	Is this individual cu	irrently o	a Hospital In	patient? (Yes (ON C
☐ Commercial ☐ Medicaid	Name of Insuranc	ce Carri	er	Insurance	ID#:	
☐ Medicare ☐ Tricare	Relationship to Ins	_	ild Oothe	r:		
□ CHAMPVA				Policy Holder's Date of Birth		
FOR ALL INSURANCE PROVIDE FRONT	Referral/Prior Authorization #			Hold test for cost estimate and		
AND BACK COPY OF CARD(S)	(please attach) Secondary Insurance Type:			is >\$250 (for in-network/ contracted commercial		
	Insurance Carrier	Insura	nce ID #	Subscribe	ce only) r Name	Date of Birtl
	Relationship to Ins	_	ild O0the	r:		
O PATIENT BILL	If Patient Bill is sele patient for this tes	ected, I	am electing	to be treat		
	claim to my insure send an invoice to	ance for	this testing	g, if I have ir	surance.	GeneDx will
	Authorized Patier	nt/Guar	dian Signa	ture		
O INSTITUTIONAL BILL	GeneDx Account #	#				-
	Hospital/Lab Nam	ie		Place	Sticker/St	tamp Here

Exchanae.

Signature of Ordering Provider

Health Information Exchange participation.

PRENATAL GENETICS TEST REQUISITION FORM



First Name Last Name Date of Birth CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED) ☐ IVF Pregnancy ☐ Egg Donor ☐ Sperm Donor Last Menstrual Period (mm/dd/yy): _ **ULTRASOUND INFORMATION/FINDINGS** Date of Ultrasound (mm/dd/yy): GA at time of Ultrasound: Weeks Days Please check all that apply. This is not a substitute for submitting clinical records. **Pre/Perinatal History Eye Defects/ Vision Genitourinary Findings** ☐ Cystic hygroma Anophthalmia ☐ Ambiguous genitalia ☐ Diaphragmatic hernia Microphthalmia ☐ Cystic renal dysplasia ☐ Encephalocele ☐ Horseshoe kidney ☐ Increased nuchal translucency **Cardiac Findings** ☐ Polycystic kidney dysplasia ☐ Atrial septal defect ☐ Intrauterine growth retardation ☐ Renal agenesis ☐ Maternal diabetes mellitus ☐ Cardiac rhabdomyoma ☐ Umbilical hernia □ Neural tube defect ☐ Heterotaxy ☐ Tetralogy of Fallot ☐ Nonimmune hydrops fetalis Other Indications for Testing ☐ Oligohydramnios ☐ Ventricular septal defect \square AMA ☐ Abnormal maternal serum screen for: ☐ Omphalocele □ Polvhvdramnios **Gastrointestinal Findings** ☐ Increased nuchal fold (___ ☐ Congenital diaphragmatic hernia ☐ Abnormal cffDNA for: mm) ☐ Duodenal stenosis/atresia **Structural Brain Abnormalities** □ Gastroschisis ☐ Abnormal myelination ☐ Omphalocele ☐ Abnormality of periventricular white matter ☐ Abnormality of the corpus callosum **Musculoskeletal Findings** ☐ Arnold Chiari malformation ☐ Abnormal form of the vertebral bodies ☐ Abnormality of the ribs ☐ Cerebellar atrophy ☐ CNS hypomyelination ☐ Abnormality of the upper limb ☐ Cortical dysplasia Attach pedigree and/or include additional ☐ Arthrogryposis ☐ Cortical tubers ☐ Bowing of the long bones clinical information: ☐ Holoprosencephaly □ Ectrodactyly ☐ Hydrocephalus ☐ Fractures of the long bones Lissencephaly ☐ Limb joint contracture ☐ Pachygyria ☐ Multiple prenatal fractures □ Polymicrogyria □ Polydactyly □ Ventriculomegaly ☐ Scoliosis ☐ Small chest circumference Craniofacial/Dysmorphism □ Syndactyly ☐ Talipes equinovarus ☐ Cleft lip ☐ Cleft palate ☐ Thoracic hypoplasia ☐ Macrocephaly ☐ Microcephaly OTHER RELEVANT INFORMATION (SUMMARIZE OR ATTACH REPORTS) ☐ Chromosomes/FISH: ☐ Fetal MRI/CT: ☐ Other relevant results (clinical or research): ☐ Array CGH: _____ ☐ Fetal echo: ☐ Previous relevant pregnancy and/or family history (attach pedigree):

Please choose test(s) and provide clinical information in the appropriate section above. GeneDx performs maternal contamination studies for prenatal tests, so a maternal blood sample is requested for prenatal tests. All tests will be performed concurrently unless order of testing is specified.



PRENATAL GENET	103 11	SI KE	QUISTTION	-ORIVI		OE	I ICLX
First Name Last Name					Date of Birth		
FAMILY HISTORY							
□ No Known Family History	□P€	edigree Att	ached	□ Adopted			
Relationship	Maternal	Paternal		Relevant i	listory		Age at Dx
1	0	0					
2	0	0					
3	0	0					
			PREVIOUS GEN	IETIC TESTING			
Personal or family history of c	nenetic test	ing ON		ease complete all field	ds below)		
Relation to patient (self, sibling, et			<u> </u>	<u> </u>		v plagos glas provida thair g	occasion #:
Relation to patient (sell, sibling, et	.c.), Gerietic 1	est(s) and k	esuit (e.g. positive, negi	ative, etc.). Il relative was	tested at Geneb	x, piease also provide trieli ai	cession #.
If patient or relative(s) were found Indicate any Variants of Interest‡			S result on prior testing	, please provide details b	elow.		
Relation (self, sibling, etc.)	Gene	Transcrip	t# c./p. (SN	V) or exon # (CNV)	Build,	coordinates (CNV)	Variant of Interest‡?
1							
2							
3							
Required for sequence variants: gene, c./p., transcript #							
Required for CNVs: gene, transcript #,		d, coordinates					
Abnormal karyotype, FISH, or othe	er results.						
‡ For certain tests, GeneDx may be abl	e to specifically	comment un	on the presence or absence	e of previously identified varia	ant(s) of interest in	the report. Complete variant info	rmation
must be provided in the table above at not be possible to comment upon the	t the time the te	est order is pla	ced. If you do not complete	the table above and check of	off that a previously	identified variant is a variant of i	
						· · · · · · · · · · · · · · · · · · ·	
			TARCETER VAL	DIANT TESTING			
Please contact GeneDx (prer	natal@aene	edy com) n	TARGETED VAI		riant testina		
☐ 902 Prenatal Testing for					<u>_</u>	ormalities () Unknown	
Affected Relative Name			tionship to Fetus		GeneDx Access		
☐ Known Familial Sequence Variant ☐ Known Familial Copy Number Variant							
Prenatal known variant testing will <u>NOT</u> be initiated until all appropriate positive control samples have been received. Non-GeneDx Test: Relative tested at GeneDx (provide GeneDx ID number above)							
Positive control included/will be sent - Positive control is REQUIRED if previous test was performed at another lab. Family member test report included (REQUIRED if previous test was performed at another lab)							
VARIANT INFORMATION (please fill out the below information if family member report is not included) Number of Variants:							
·			Amino Acid (p.)		Transcript (NM#)		
Gene	Coding	g DNA (c./m.)		Amino Acid (p.)		Transcript (NM#)	
COPY NUMBER VARIANT	COPY NUMBER VARIANT Number of Variants:						
Gene(s)							
Gene(s)	Exon #	<u> </u>		Coordinates		Genome Build	

PRENATAL GENETICS TEST REQUISITION FORM



			•				
First Name		L	ast Name			Date of Birth	
			PRENATAL G	ENETIC TESTIN	G		
TEST CODE	Т	EST NAME		TEST CODE	TES	ST NAME	
NOONAN	SPECTRUM AND RASOP	ATHIES			•		
□ 357	Prenatal Noonan Spectrur	m Disorders P	anel				
SKELETAL	AND LIMB ABNORMALIT	IES					
□ 949	Prenatal Skeletal Dysplasio	a Panel					
BRAIN MA	LFORMATIONS						
☐ J803	Prenatal Joubert Syndrom	ne and Relate	d Disorders Panel	☐ TL54	Prenatal X-Linked Hydroceph	nalus/MASA/CRASH Syndrome	
OTHER PA	NELS			'			
☐ TG85	Prenatal Akinesia/Arthrog	ryposis Panel		☐ TF33	Prenatal Spinal Muscular Atro	ophy	
☐ TF32	Prenatal Fragile X Syndron	ne		□ 934	Prenatal Tuberous Sclerosis		
☐ TG16	Prenatal Myotonic Dystrop	ohy 1		-	1		
CYTOGEN	OMIC TEST						
□ 460	Prenatal/POC Whole Gend	me Chromos	somal Microarray (CMA))			
Notes: (1) If sufficient fetal material is submitted, most testing can be performed concurrently. If no other instructions are given, all tests will be performed concurrently. (2) If you choose to have the testing done in a particular order ('reflex testing'), indicate the order of tests by numbering the tests (Example: (1) Prenatal targeted array; (2) Noonan syndrome testing (if array normal)).							
PRENATAL PARENT TESTING							
I authorize GeneDx to automatically reflex to test parental samples for any variant of uncertain clinical significance detected on the above ordered molecular test(s).							
Biological	irst Name	Last Name	DOE	0	Asymptomatic O Symptom	atic	
Mother				-	At GeneDx (Accession #: Not available O Submit with) n fetal specimen	
F	irst Name	Last Name	DOE		Asymptomatic Osymptome	· · · · · · · · · · · · · · · · · · ·	
Biological					At GeneDx (Accession #:)	
Father				0	Not available O Submit with	fetal specimen	
DID YOU REMEMBER TO?							
☐ Label spe	☐ Label specimen tube appropriately with TWO identifiers						

GeneDx tests are frequently updated and improved based upon the most recent scientific evidence. The test codes, genes, and gene quantities listed on this test requisition are subject to change by GeneDx at any time. The most current test menu, list of genes, and technical limitations included for a specific test panel may be found on our website, genedx.com. Please note that GeneDx reserves the right to modify and upgrade any ordered panel to the version currently listed on our website.

 $\hfill \square$ Get a signature for medical necessity and patient consent

INFORMED CONSENT



First Name Last Name Date of Birth

For the purposes of this consent, "I", "my", and "your" will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or pass on a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

- 1. <u>Positive</u>: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.
- 2. <u>Negative</u>: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.
- 3. <u>Variant of Uncertain Significance (VUS)</u>: A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.
- 4. <u>Unexpected Results (ACMG Secondary Findings)</u>: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. We may disclose this information to the ordering healthcare provider if it likely affects medical care.

Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information GeneDx used to interpret my results. Healthcare providers can contact GeneDx at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of the test results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents.

Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that GeneDx will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information about a relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

- 1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.
- 2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.
- 3. Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.
- 4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.
- 5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.

To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information. More information can be found at: www.genome.gov/10002077

SAMPLE RETENTION

After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. GeneDx will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made.

I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and GeneDx will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. GeneDx will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION

De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this de-identified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. GeneDx shares this type of information with healthcare providers, scientists, and healthcare databases. GeneDx will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. GeneDx believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.

EPILEPSY PARTNERSHIP PROGRAM PARTICIPATION

I understand that GeneDx will send de-identified test results data, excluding ACMG secondary findings, to third parties for research or commercial purposes and that GeneDx is compensated for the provision of testing services and for data sharing with third parties that is compliant with applicable law. At no time will GeneDx share any patient personally identifiable information. GeneDx may share contact information for providers listed on the Test Requisition Form with third parties.

INFORMED CONSENT



First Name	Last Name	Date of Birth

PATIENT RECONTACT FOR RESEARCH PARTICIPATION

GeneDx may collaborate with other scientists, researchers and drug developers to advance knowledge of genetic diseases and to develop new treatments. If there are opportunities to participate in research relevant to the disorder in (my/my child's) family, GeneDx may contact my healthcare provider for research purposes, such as the development of new testing, drug development, or other treatment modalities. In some situations, such as if my healthcare provider is not available, I may be contacted directly. I can opt out of being contacted directly regarding any of the above activities by having my healthcare provider check the box for Patient Research Opt-Out. Any research that results in medical advances, including new products, tests or discoveries, may have potential commercial value and may be developed and owned by GeneDx or the collaborating researchers. If any individuals or corporations benefit financially from these studies, no compensation will be provided to (me/my child) or to (my/my child's) heirs.

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

- · Applicable only for full exome sequencing and genome sequencing tests
- Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features.

The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT?

All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing or a minimum of 15X coverage was achieved by genome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES?

The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS

Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified nor reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE

For insurance billing, I understand and authorize GeneDx to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to GeneDx.

I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by GeneDx as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by GeneDx on my behalf, I agree to endorse the insurance check and forward it to GeneDx within 30 days of receipt as payment towards GeneDx's claim for services rendered.

rego to p fam any	By signing this form: (i) I acknowledge that I have read or have had read to me the GeneDx Informed Consent document, and understand the information regarding genetic testing; (ii) I have had the opportunity to ask questions about the testing, the procedure, the risks, and the alternatives; (iii) I authorize GeneDx to perform genetic testing as ordered; (iv) I understand that, for tests that evaluate data from multiple family members concurrently, test results from these family members may be included in a single comprehensive report that will be made available to all tested individuals and their healthcare providers; (v) if at any time I or my provider provide an email address or mobile phone number at which I may be contacted, I consent to receiving email or text messages from GeneDx; and (vi) I understand that this consent applies to all future communications unless I request a change in writing.						
	Secondary Findings Opt-out. Check this box if you do not wish to receive ACMG secondary findings (Full Exome Sequencing and Genome Sequencing Tests ONLY; not for Xpanded® or Slice tests).						
	New York Retention Opt-in. By checking this box, I confirm that I am a New York State resident, and I give permission for GeneDx to retain any remaining sample longer than 60 days after the completion of testing, and to be used as a de-identified sample for test development and improvement, internal validation, quality assurance, and training purposes. Otherwise, New York law requires GeneDx to destroy my sample within 60 days, and it cannot be used for test development studies.						
	Patient Research Opt-out. Check this box if you wish to opt out of being con	stacted for research studies.					
	Health Information Exchange Opt-in. Check this box if you reside in CA, FL, MA, NV, NY, RI, and VT and wish to opt-in to my health information to be shared for Health Information Exchange participation.						
	Health Information Exchange Opt-out. Check this box if you reside in any other US state or territory and wish to opt-out of participation in Health Information Exchange.						
Signo	ignature of Patient/Legal Guardian (required) Date						
signature of Relative A/Legal Guardian Relative A Relationship to Patient Date							
igna	ture of Relative B/Legal Guardian	Relative B Relationship to Patient	Date				